Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Latest approved therapies for metastatic melanoma: what comes next?

Menaa F.

J Skin Cancer. 2013;2013:735282. doi: 10.1155/2013/735282. Epub 2013 Feb 24.

2.

[Unblocking antitumor immune response: novel possibilities for the immunotherapy of melanoma].

Ladányi A, Balatoni T.

Magy Onkol. 2013 Jun;57(2):100-7. doi: MagyOnkol.2013.57.2.100. Epub 2013 Apr 28. Review. Hungarian. Erratum in: Magy Onkol. 2014 Apr;58(1):51.

3.

Current and future roles of targeted therapy and immunotherapy in advanced melanoma.

Olszanski AJ.

J Manag Care Spec Pharm. 2014 Apr;20(4):346-56. Review.

4.

Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma.

Natarajan N, Telang S, Miller D, Chesney J.

Drugs. 2011 Jul 9;71(10):1233-50. doi: 10.2165/11591380-000000000-00000. Review.

PMID:
21770473
5.

CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.

Camacho LH.

Cancer Med. 2015 May;4(5):661-72. doi: 10.1002/cam4.371. Epub 2015 Jan 25. Review.

6.

The role of BRAF V600 mutation in melanoma.

Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N.

J Transl Med. 2012 Jul 9;10:85. doi: 10.1186/1479-5876-10-85.

7.

Upcoming strategies for the treatment of metastatic melanoma.

Spagnolo F, Queirolo P.

Arch Dermatol Res. 2012 Apr;304(3):177-84. doi: 10.1007/s00403-012-1223-7. Epub 2012 Feb 17. Review.

PMID:
22350184
8.

Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.

Grimaldi AM, Simeone E, Festino L, Vanella V, Palla M, Ascierto PA.

Discov Med. 2015 Jun;19(107):455-61. Review.

9.

BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro.

Gargett T, Fraser CK, Dotti G, Yvon ES, Brown MP.

J Immunother. 2015 Jan;38(1):12-23. doi: 10.1097/CJI.0000000000000061.

PMID:
25415284
10.

Ipilimumab and vemurafenib: two different routes for targeting melanoma.

Burgeiro A, Mollinedo F, Oliveira PJ.

Curr Cancer Drug Targets. 2013 Oct;13(8):879-94. Review.

PMID:
23862981
11.

[Advances in clinical treatment of malignant melanoma: B-RAF kinase inhibition].

Heneberg P.

Klin Onkol. 2011;24(4):256-64. Review. Czech.

PMID:
21905615
12.

Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.

Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong XQ, Buchanan S, Henry JR, Starling JJ, Peng SB.

J Biol Chem. 2012 Aug 10;287(33):28087-98. doi: 10.1074/jbc.M112.377218. Epub 2012 Jun 22.

13.

New drugs in melanoma: it's a whole new world.

Eggermont AM, Robert C.

Eur J Cancer. 2011 Sep;47(14):2150-7. doi: 10.1016/j.ejca.2011.06.052. Epub 2011 Jul 27. Review.

PMID:
21802280
14.

Immunotherapy in Melanoma: Recent Advances and Promising New Therapies.

Saraceni MM, Khushalani NI, Jarkowski A 3rd.

J Pharm Pract. 2015 Apr;28(2):193-203. Epub 2014 Mar 27.

PMID:
24674910
15.

Vemurafenib and ipilimumab: new agents for metastatic melanoma.

Banaszynski M, Kolesar JM.

Am J Health Syst Pharm. 2013 Jul 15;70(14):1205-10. doi: 10.2146/ajhp120260. Review.

PMID:
23820456
16.

New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.

Azijli K, Stelloo E, Peters GJ, VAN DEN Eertwegh AJ.

Anticancer Res. 2014 Apr;34(4):1493-505. Review.

PMID:
24692676
17.

Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".

Jarkowski A 3rd, Norris L, Trinh VA.

Ann Pharmacother. 2014 Nov;48(11):1456-68. doi: 10.1177/1060028014544165. Epub 2014 Jul 23. Review.

PMID:
25056920
18.

Trametinib in metastatic melanoma.

Chopra N, Nathan PD.

Expert Rev Anticancer Ther. 2015;15(7):749-60. doi: 10.1586/14737140.2015.1060127. Review.

PMID:
26107021
19.

The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.

Zhu Z, Liu W, Gotlieb V.

Crit Rev Oncol Hematol. 2016 Mar;99:91-9. doi: 10.1016/j.critrevonc.2015.12.002. Epub 2015 Dec 10. Review.

PMID:
26708040
20.

Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach.

Davar D, Tarhini AA, Kirkwood JM.

Clin Dermatol. 2013 May-Jun;31(3):237-50. doi: 10.1016/j.clindermatol.2012.08.012. Review. Erratum in: Clin Dermatol. 2013 Jul-Aug;31(4):501.

Supplemental Content

Support Center